Servier drug Tibsovo is now approved for treating advanced cases of myelodysplastic syndrome that have an IDH1 mutation. It’s the first approval of a targeted therapy for this type of cancer.
Agios Pharmaceuticals sold royalties to an approved cancer drug to get immediate cash to support its new focus on rare diseases. Earlier this year, the FDA approved the biotech’s first rare disease drug, a treatment for a type of anemia.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
The company announced the presentation of data at the ESMO meeting in Barcelona for Tibsovo, in patients with IDH1-mutant bile duct cancer. The drug is approved for treating IDH1-mutation positive acute myeloid leukemia.